Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business UpdateGlobeNewsWire • 05/06/25
Allogene Therapeutics to Present Updated ALLO-316 Clinical Results in Kidney Cancer in Oral Presentation and ALPHA3 Trial-in-Progress Poster for Cema-Cel at the 2025 American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewsWire • 04/23/25
FDA Grants Three Fast Track Tags to Allogene's Autoimmune Disease DrugZacks Investment Research • 04/08/25
Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and SclerodermaGlobeNewsWire • 04/07/25
Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business UpdateGlobeNewsWire • 03/13/25
Allogene Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business UpdateGlobeNewsWire • 03/03/25
Allogene Therapeutics Expands Strategic Partnership with Foresight Diagnostics to Advance Joint Development Activities Outside the US Across Europe, UK, Canada, and AustraliaGlobeNewsWire • 02/25/25
Allogene Therapeutics Announces Publication of Durable Response Data from Phase 1 ALPHA/ALPHA2 Trials of the Allogeneic CAR T Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma in the Journal of Clinical OncologyGlobeNewsWire • 02/13/25
Allogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune DiseasesGlobeNewsWire • 01/28/25
Allogene Therapeutics (ALLO) Upgraded to Buy: What Does It Mean for the Stock?Zacks Investment Research • 12/26/24
Allogene Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 12/16/24
Allogene Therapeutics Acknowledges the Passing of Founding Board Member David BondermanGlobeNewsWire • 12/12/24
Allogene Therapeutics Loses 23% Year to Date: How to Play the Stock?Zacks Investment Research • 12/02/24
Allogene Therapeutics Announces Participation in December Investor ConferencesGlobeNewsWire • 11/19/24
Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) ConvergenceGlobeNewsWire • 11/18/24